Subscribe Become an Author Add Company Sign Up Log In

GNS Healthcare

GNS Healthcare

Private company

We solve healthcare’s matching problem. We provide technology, services, and solutions that precisely match health interventions to individuals, helping our clients improve health outcomes and avoid the billions of healthcare dollars wasted on ineffective treatments.

By making the precise matching of interventions to individuals possible, we create data-driven evidence to define what works for whom and puts that knowledge within reach for health plans, health systems, biopharmaceutical companies, and foundations and researchers who are working toward improving health outcomes, patient by patient.

Private company
United States of America based
$36.100 M
Research papers
Product type
  • Therapies
Research focus
  • Clinical Development
  • Data mining / Ontology building
  • Pharmacovigilance

Investing history

2017Unknown Round6.0
2016Unknown Round4.0
2015Unknown Round0.75
2014Series B10.0
2013Series A9.9
2012Unknown Round5.0
2010Unknown Round0.45

Press releases

    No mentions found

Posts Mentioning This Company

Biopharma Insights


No products posted yet


No services posted yet

Clinical Trials

    No clinical trials found


    No patents found

Publications (PubMed)
  • 32084987 (from 2020-02-23), Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC).
  • 32060406 (from 2020-02-16), Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
  • 32009223 (from 2020-02-06), Application of Machine Learning Models to Evaluate Hypoglycemia Risk in Type 2 Diabetes.
  • 29410046 (from 2018-02-08), Systems biology and in vitro validation identifies family with sequence similarity 129 member A (FAM129A) as an asthma steroid response modulator.
  • 29047368 (from 2017-10-20), Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations.
  • 28958801 (from 2017-09-30), Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
  • 28629454 (from 2017-06-21), Impact of pharmacy channel on adherence to oral oncolytics.
  • 28604798 (from 2017-06-13), A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease.
  • 28087598 (from 2017-01-15), Bayesian Network Inference Modeling Identifies TRIB1 as a Novel Regulator of Cell-Cycle Progression and Survival in Cancer Cells.
  • 27829029 (from 2016-11-10), Inferring Gene Networks for Strains of Dehalococcoides Highlights Conserved Relationships between Genes Encoding Core Catabolic and Cell-Wall Structural Proteins.
  • 26963550 (from 2016-03-11), Community crystal gazing.
  • 26849111 (from 2016-02-06), The HTT CAG-Expansion Mutation Determines Age at Death but Not Disease Duration in Huntington Disease.
  • 26685993 (from 2015-12-22), Reverse Engineering and Evaluation of Prediction Models for Progression to Type 2 Diabetes: An Application of Machine Learning Using Electronic Health Records.
  • 26679960 (from 2015-12-19), Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
  • 25180505 (from 2014-09-03), Novel predictive models for metabolic syndrome risk: a "big data" analytic approach.

Assets (therapeutic products)

    No assets found

Year Partner Focus Amount of Deal

(2016, Jan. 1)
Celgene -- --

(2017, Jan. 1)
Genentech -- --

(2018, Jan. 1)
Amgen The goal of the collaboration is to better understand the factors that drive and predict a patient’s response to Amgen’s metastatic CRC treatment, panitumumab. --